Booster Vaccination Study to Assess Immunogenicity % Safety of a Dose of GSK Biologicals' Mencevax™ ACWY % 1/5th of a Dose of Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study
Meningococcal Serogroups A, C, W-135 and Y Vaccine
Infections, Meningococcal
Phase 3
This is a follow up study to 100478. The results are summarized with study 105239 on the GSK Clinical Study Register. An annotated case report form is not available for this study. A blank case report form will be provided
October 2014